Fidaxomicin

This classification denotes a macrolide antibiotic with the molecular formula C52H74Cl2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5N076G8YQ, chemically known as [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl]3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate but generally known as Fidaxomicin, which bears US NIH Compound Identifier 10034073. European Medicines Agency schedules Fidaxomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31455. The term FIDAXOMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Vol 23, No. 3, 2009, List 62.). As of Q4 2014, FIDAXOMICIN remains the US FDA Preferred Term for this commodity. Fidaxomicin bears US NLM identifiers UMLS ID C0065023 and NCI Concept Code C66979. SMILES: CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C.